Does Rallies show Form 4 insider transactions for DRIO?

Yes. Rallies tracks DRIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DRIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DRIO. It does not provide personalized investment advice.

DRIO (DarioHealth Corp. Common Stock) Stock Analysis - Insider Trades

DarioHealth Corp. Common Stock (DRIO) is a publicly traded Healthcare sector company. As of May 21, 2026, DRIO trades at $8.13 with a market cap of $61.06M and a P/E ratio of 1.46. DRIO moved -2.44% today. Year to date, DRIO is -23.95%; over the trailing twelve months it is -39.39%. Its 52-week range spans $5.94 to $31.00. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces DRIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DRIO stock inside the company?

Recent DRIO insider activity includes Nelson Steven Charles bought 40.00K, Nelson Steven Charles bought 5.00K, Nelson Steven Charles bought 5.00K, Nelson Steven Charles bought 5.00K, and Nelson Steven Charles bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DRIO Key Metrics

Key financial metrics for DRIO
Metric	Value
Price	$8.13
Market Cap	$61.06M
P/E Ratio	1.46
EPS	$5.46
Dividend Yield	0.00%
52-Week High	$31.00
52-Week Low	$5.94
Volume	20
Avg Volume	0
Revenue (TTM)	$21.19M
Net Income	$-40.74M
Gross Margin	56.55%

Recent DRIO Insider Trades

Nelson Steven Charles bought 40.00K (~$21.20K) on Aug 27, 2025.
Nelson Steven Charles bought 5.00K (~$4.55K) on Nov 12, 2024.
Nelson Steven Charles bought 5.00K (~$4.02K) on Sep 11, 2024.
Nelson Steven Charles bought 5.00K (~$4.22K) on Sep 10, 2024.
Nelson Steven Charles bought 5.00K (~$4.00K) on Sep 9, 2024.

Latest DRIO News

DarioHealth Q1 Revenue Up 24% to $14.8M, EBITDA Loss Narrows — May 13, 2026
DarioHealth Reports 6.7 % Sequential Revenue Growth, Access to 116 Million Covered Lives — May 13, 2026
DarioHealth Study Finds 1,254 Users Achieve Significant Productivity Gains by Week Six — Apr 20, 2026
DarioHealth Appoints 40-Year Executive to Drive Multibillion-Dollar Commercial Partnerships — Apr 13, 2026
DarioHealth Signs 85 Contracts for $12.9M, Eyes $38-42M Break-Even Revenue — Mar 19, 2026

DRIO Analyst Consensus

2 analysts cover DRIO: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.

Common questions about DRIO

Who is trading DRIO stock inside the company?: Recent DRIO insider activity includes Nelson Steven Charles bought 40.00K, Nelson Steven Charles bought 5.00K, Nelson Steven Charles bought 5.00K, Nelson Steven Charles bought 5.00K, and Nelson Steven Charles bought 5.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DRIO?: Yes. Rallies tracks DRIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DRIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DRIO. It does not provide personalized investment advice.